Keytruda, a medication produced by Merck & Co. for the treatment of various forms of cancer, received its first approval from the U.S. Food and Drug Administration (FDA) on September 4, 2014 [1]. This approval was for the treatment of advanced melanoma, a type of skin cancer. Since then, Keytruda has received additional approvals from the FDA for the treatment of other cancer types, including lung, head and neck, classical Hodgkin lymphoma, and urothelial carcinoma [1].

It is important to note that while Keytruda has received FDA approval for these uses, it does not necessarily mean that it is covered by insurance or that it is the best treatment option for every patient. Patients should consult with their healthcare providers to determine the most appropriate treatment plan for their individual circumstances.

Sources:
[1] DrugPatentWatch.com, "Keytruda (pembrolizumab) - Patent Expiration & Drug Sales", <https://www.drugpatentwatch.com/patent/keytruda-pembrolizumab/>